Medicine Advances最新文献

{"title":"Case Report: Abemaciclib-Induced Chronic Renal Failure","authors":"Lu Lin,&nbsp;Jinhui Chen,&nbsp;Jing Li,&nbsp;Shuangxin Liu,&nbsp;Weihua Lai","doi":"10.1002/med4.70017","DOIUrl":"https://doi.org/10.1002/med4.70017","url":null,"abstract":"<p>Abemaciclib, a cyclin-dependent kinase 4/6 inhibitor, may induce kidney damage during the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. We report a case of a 52-year-old woman with normal baseline kidney function (serum creatinine, 68.19 μmol/L; eGFR, 89 mL/(min·1.73 m²); blood urea nitrogen, 7.74 mmol/L; cystatin C, 0.74 mg/L) who developed stage 2 chronic kidney disease after 12 months of abemaciclib therapy (150 mg/day, twice daily). Three months after discontinuation, kidney function recovered (serum creatinine, 73.80 μmol/L; normalized cystatin C and uric acid), but creatinine rose again to 92.5 μmol/L within 1 month of reinitiation. This case suggests that long-term abemaciclib use may lead to kidney damage, potentially progressing to chronic kidney failure. Regular monitoring of renal function indicators is recommended before and during treatment.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"112-115"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiomics-Based CT Prediction of KRAS/NRAS/BRAF Mutation Status in Colorectal Cancer: A Multicenter Study","authors":"Yinrui Yang,&nbsp;Caixia Zhang,&nbsp;Daxiu Fu,&nbsp;Jinyu Chen,&nbsp;Xin Zhang,&nbsp;Zongsheng Pu,&nbsp;Guanshun Wang,&nbsp;Zhenhui Li","doi":"10.1002/med4.70012","DOIUrl":"https://doi.org/10.1002/med4.70012","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Colorectal cancer (CRC) is a common malignancy with high morbidity and mortality. Kirsten rat sarcoma viral oncogene homolog (KRAS), neuroblastoma RAS viral oncogene homolog (NRAS), and B-Raf proto-oncogene serine/threonine kinase (BRAF) mutations are key biomarkers for targeted therapy. Radiomics offers a non-invasive approach to predict genetic alterations using CT imaging. The aim of this study was to develop a predictive model for KRAS/NRAS/BRAF gene mutations in colorectal cancer using radiomic characteristics obtained from computed tomography (CT) imaging.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 385 patients diagnosed with colorectal cancer were enrolled in this retrospective multicenter study. Radiomic features were extracted by delineating volumes of interest on venous-phase CT scans. Feature selection was performed using Pearson correlation analysis and the least absolute shrinkage and selection operator (LASSO) algorithm, and a radiomic model was constructed using a support vector machine. Logistic regression was used to develop the clinical model and the combined clinical-radiomic model. The predictive performance of the models was evaluated using receiver operating characteristic curve analysis, calibration curve assessment, and decision curve analysis. Additionally, heatmaps and Shapley additive explanation plots were used to enhance the interpretability of the models.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Post feature selection and dimension reduction, a total of six features were maintained for the construction of the radiomic model. In the training dataset, the radiomic model secured an area under the curve of 0.825 (95% CI: 0.769–0.883) compared with 0.821 (95% CI: 0.735–0.908) for the internal validation dataset and 0.818 (95% CI: 0.724–0.912) for the external test dataset. The levels of N stage and Carbohydrate antigen 199 demonstrated a notable correlation with the presence of KRAS/NRAS/BRAF mutations in the treatment of colorectal cancer (&lt;i&gt;p&lt;/i&gt; &lt; 0.05). When combined, the clinical-radiomic model exhibited enhanced diagnostic precision over using only radiomic models.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The results demonstrated a correlation between radiomic attributes from CT scans and KRAS/NRAS/BRAF mutations with an improvement in diagnostic efficacy when integrated with relevant clinical factors. CT scans could be a crucial instrument in assessing the genetic state of tumors in colorectal cancer patients, possibly assisting in the formulatio","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 3","pages":"218-230"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: Enhancing Post-Surgical Outcomes and Overcoming Relapse","authors":"Jawairya Muhammad Hussain,&nbsp;Saim Mahmood Khan,&nbsp;Haiqa Sultan,&nbsp;Diya Rathi,&nbsp;Eyob Mekonnen Woldeyohannes,&nbsp;Zemichael Getu Alemayehu","doi":"10.1002/med4.70019","DOIUrl":"https://doi.org/10.1002/med4.70019","url":null,"abstract":"<p>Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that's usually detected at an advanced stage and has a high recurrence rate despite surgical resection, making treatment challenging. Although mitotane is still the only approved treatment, its poor effectiveness has raised interest in immunotherapy with immune checkpoint inhibitors (ICIs) such as avelumab, nivolumab, and pembrolizumab. By addressing ACC's immune response, ICIs and surgery together are intended to improve post-operative results and lower recurrence.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 3","pages":"205-208"},"PeriodicalIF":0.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70019","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145196844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"LINC00922: A Critical Oncogenic Long Non-Coding RNA Involved in Cancer Progression, Chemotherapy Resistance, and microRNA Regulation","authors":"Jiahua Si,&nbsp;Chenhao Liang,&nbsp;Xueting Zhang,&nbsp;Hening Xu,&nbsp;Xinming Su,&nbsp;Luqing Liu,&nbsp;Ruyi Yuan,&nbsp;Yuemin Ding,&nbsp;Shiwei Duan","doi":"10.1002/med4.70018","DOIUrl":"https://doi.org/10.1002/med4.70018","url":null,"abstract":"<p>LINC00922, a long non-coding RNA (lncRNA) located at chromosome 16q21, has emerged as a crucial regulatory molecule in cancer progression, chemotherapy resistance, and immune modulation. This lncRNA is predominantly localized in the cytoplasm, with limited expression in the nucleus and exosomes. Elevated LINC00922 expression levels are associated with poor patient prognosis across various cancer types. LINC00922 can regulate cancer cell behavior through complex gene regulatory networks, including interactions with several key signaling pathways, such as the Wnt, telomerase, and immune response pathways. Importantly, LINC00922 participates in multiple competing endogenous RNA axes, influencing the expression patterns of target microRNAs like miR-424-5p and miR-874-3p, which in turn regulate important cancer-related genes, such as TFAP2C and GDPD5 contributing to chemotherapy resistance. LINC00922 can also promote immune cell infiltration in tumors, with its high expression levels correlating with extensive immune cell presence, suggesting potential for cancer immunotherapy. Despite these promising findings, the upstream regulatory factors of LINC00922 remain poorly understood and further research is needed to fully uncover its clinical potential. In this review, we highlight the multifaceted roles of LINC00922 in cancer, emphasizing the need for future studies to explore its potential as a therapeutic target and diagnostic biomarker.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"65-79"},"PeriodicalIF":0.0,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships Between Serum Vitamin D, Inflammatory Markers, and Outcomes in Non-Critically Ill Patients With COVID-19: A Cross-Sectional Study","authors":"Zahra Khorasanchi,&nbsp;Ali Jafazadeh Esfehani,&nbsp;Mohammad Reza Shadmand Foumani Moghadam,&nbsp;Sara Shojaei Saadatqoli,&nbsp;Payam Sharifan,&nbsp;Majid Ghayour Mobarhan,&nbsp;Sajjad Arefinia,&nbsp;Afshin Roghani,&nbsp;Naghme Mirhossini,&nbsp;Masoud Pezeshki Rad,&nbsp;Saeid Eslami,&nbsp;Hamidreza Naderi,&nbsp;Hassan Vatanparast,&nbsp;Reza Rezvani","doi":"10.1002/med4.70010","DOIUrl":"https://doi.org/10.1002/med4.70010","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Backround</h3>\u0000 \u0000 <p>Treatment options for COVID-19 remain limited and are primarily focused on specific patient populations; accordingly, preventive measures continue to be a crucial aspect of effective management. There is evidence that vitamin D effectively prevents viral upper respiratory tract infections during epidemics. The aim of this study was to assess the association between serum vitamin D and inflammatory markers, mortality, and clinical symptoms in patients with COVID-19.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study involved non-critically ill patients with COVID-19 in a provincial reference hospital in Mashhad, Iran. Demographic and clinical data were extracted from patient medical records. Serum vitamin D was measured for each patient within 12 h of admission. Data were analyzed using linear and logistic regression models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 452 patients (mean age 63.87 ± 17.97 years) were included in this study during 2 months of data collection. The most common serum vitamin D status was sufficient (30.0%), followed by deficient (29.4%), insufficient (23.2%), and severely deficient (17.3%). Partial symptom improvement was observed in 326 (72.1%) patients after 22 days of hospitalization, disregarding the vitamin D status. The mortality rate was 22.6%. COVID-19 mortality was significantly related to serum urea (<i>p</i> = 0.002, OR = 1.020, 95% CI: 1.008–1.033), pulse rate (<i>p</i> = 0.015, OR = 1.047, 95% CI: 1.009–1.086), and age (<i>p</i> = 0.002, OR = 1.076, 95% CI: 1.027–1.127).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Among patients with COVID-19, serum vitamin D levels were linked to mortality and some clinical parameters, including urea and pulse rate. Further longitudinal studies should evaluate the relationship between serum vitamin D levels and COVID-19 outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"97-106"},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticipating On-Target and Off-Target Effects of CRISPR/Cas9 Genome Editing Via a Feedforward Neural Network Model","authors":"Pavithra Nagendran,&nbsp;Gowtham Murugesan,&nbsp;Jeyakumar Natarajan","doi":"10.1002/med4.70016","DOIUrl":"https://doi.org/10.1002/med4.70016","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Clustered regularly interspaced short palindromic repeats —CRISPR-associated protein 9 (CRISPR/Cas9) is a gene editing technology that can deliver highly precise genome editing. However, it is difficult to predict both on- and off-target effects of CRISPR/Cas9, which is essential for ensuring the safety and efficiency of genetic modifications made using this technology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this study, we used the SITE-Seq dataset, which comprises CRISPR targets, to classify sequences for both on- and off-target effects. To evaluate sequence pairs, we built a feedforward neural network (FNN) with 10 fully connected layers and compared its performance with that of other state-of-the-art models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We showed that our FNN model attained an accuracy rate of 0.95, greatly improving prediction reliability for both on- and off-target effects compared with other methods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This work contributes a valuable predictive modeling framework to the field of CRISPR research, addressing both on- and off-target effects in a unified manner, which is an essential requirement for the safe and effective application of genomic editing technologies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"88-96"},"PeriodicalIF":0.0,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70016","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing Heart Health: Expanding the Use of SGLT2 Inhibitors in Cardiovascular Disease","authors":"Manahil Mubeen,&nbsp;Aasiya Shahbaz Sakarwala,&nbsp;Arif Imdad Bijarani,&nbsp;Muhammad Taha Kamal","doi":"10.1002/med4.70014","DOIUrl":"https://doi.org/10.1002/med4.70014","url":null,"abstract":"<p>SGLT2 inhibitors offer multifaceted cardiovascular benefits, including improved cardiac metabolism, reduced preload and afterload, and decreased myocardial infarction risk. These effects are driven by renoprotection, anti-inflammatory properties, improved mitochondrial function, osmotic diuresis, and glycemic control. Together, these mechanisms support the role of SGLT2 inhibitors in reducing cardiovascular morbidity and mortality.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"122-126"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Xanomeline-Trospium Chloride (Cobenfy): A New Era in Managing Schizophrenia—Comparative Effectiveness and Economic Challenges","authors":"Jawairya Muhammad Hussain,&nbsp;Wajiha Arif,&nbsp;Sharjeel Humayun,&nbsp;Nida Shoaib,&nbsp;Saim Mahmood Khan","doi":"10.1002/med4.70013","DOIUrl":"https://doi.org/10.1002/med4.70013","url":null,"abstract":"<p>Xanomeline-trospium chloride (cobenfy) is a muscarinic agonist used to treat hallucinations and psychotic illnesses such as Alzheimer's and Schizophrenia. It has been constructed for patients who are unable to tolerate dopamine-targeting therapies and a comparison is drawn against other similar drugs with variables like cost, mechanism of action, efficacy and contraindications taken into account. Specifically effective for schizophrenia, it is safer with fewer side effects and efficient with stronger success rates, offering pharmacists and physicians an alternative to mainstream antipsychotic drugs.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"116-121"},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical Management of a High-Grade Gastrointestinal Stromal Tumor in a Morbidly Obese Patient: A Case Study","authors":"Felipe Quistian,&nbsp;Kristen M. Quinn,&nbsp;Michael A. Deal,&nbsp;Rana Pullatt","doi":"10.1002/med4.70011","DOIUrl":"https://doi.org/10.1002/med4.70011","url":null,"abstract":"<p>Gastrointestinal stromal tumors (GISTs) are the most commonly occurring mesenchymal tumors within the gastrointestinal (GI) tract yet, those located at the gastroesophageal junction (GEJ) are rare. We present a 31-year-old woman with morbid obesity and large (4.9 cm) polypoid mass adjacent to the GEJ. She was offered a laparoscopic transgastric GIST resection and adjuvant imatinib. Intraoperatively, a gastrotomy was created through which the polypoid tumor was successfully delivered for resection. The increasing prevalence of obesity can pose unique challenges to peri-operative management. Thoughtful innovations in surgical approach can save obese patients from increased morbidity or surgical delay.</p>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"107-111"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations Between Lipids and Lipid-Lowering Drug Target Genes and Osteomyelitis: A Mendelian Randomization Analysis","authors":"Zhiyi Zhou,&nbsp;Zhehan Yang,&nbsp;Junpan Chen,&nbsp;Minghao Wen,&nbsp;Jiayuan Lei,&nbsp;Wanzhe Liao,&nbsp;Yahan Li,&nbsp;Linghui Liu,&nbsp;Ziyuan Lu","doi":"10.1002/med4.70009","DOIUrl":"https://doi.org/10.1002/med4.70009","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Lipid metabolism is a key regulator of inflammation in acute and chronic conditions. However, whether dyslipidemia is related to the process of osteomyelitis remains unclear. This study aimed to use a Mendelian randomization (MR) analysis to examine the associations between triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and osteomyelitis. Additionally, the associations between the genes corresponding to these traits and osteomyelitis were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Genetic variants associated with TG and TC were selected from the Global Lipids Genetics Consortium, while LDL-C datasets were extracted from the UK Biobank. Specifically, the lipid-lowering drug target regions were selected as proxies for drug target perturbation. Osteomyelitis was identified according to the FinnGen consortium. We also conducted supplementary analyses using C-reactive protein genome-wide association study data to examine the effect of drug targets on this inflammatory marker. Furthermore, we conducted mediation analyses focusing on several risk factors for osteomyelitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>No association was found between LDL-C, TG, or TC concentrations and osteomyelitis. Proprotein convertase subtilisin/kexin type 9 (PCSK9) was significantly associated with a lower risk of osteomyelitis (odds ratio [95% confidence interval] = 0.49 [0.32–0.76], <i>p</i> = 1.60 × 10⁻³) and a lower concentration of C-reactive protein (0.94 [0.92–0.97], <i>p</i> = 3.16 × 10⁻⁴). We found that waist circumference was an intermediate variable between PCSK9 and osteomyelitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study does not support a relationship between dyslipidemia and osteomyelitis. PCSK9 is associated with a lower risk of osteomyelitis. Our findings suggest that waist circumference is a potential mediator between osteomyelitis and PCSK9. Additionally, PCSK9 is associated with reduced CRP concentrations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":100913,"journal":{"name":"Medicine Advances","volume":"3 2","pages":"80-87"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med4.70009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144520066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}